Comparative Pharmacology
Head-to-head clinical analysis: KANTREX versus TOBRAMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANTREX versus TOBRAMYCIN SULFATE.
KANTREX vs TOBRAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Aminoglycoside antibiotic; binds to 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
Adults: Tobramycin 3-5 mg/kg/day IV divided every 8 hours, or 5-7 mg/kg/day IV once daily. For inhalation: 300 mg nebulized twice daily.
None Documented
None Documented
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 24-100 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Primarily renal (glomerular filtration) with 90-95% excreted unchanged in urine within 24 hours; biliary/fecal <1%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic